The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022
Suez Canal University
Suez Canal University
PharmaMar
Nuvation Bio Inc.
Hoffmann-La Roche
Novartis
Istituto Clinico Humanitas
The Christie NHS Foundation Trust
Taproot Health
RECORDATI GROUP
Federation Francophone de Cancerologie Digestive
Hutchmed
University Medical Center Groningen
Novartis
Novartis
Eastern Cooperative Oncology Group
Institut Curie
Johannes Gutenberg University Mainz
EMD Serono
Novartis
Philipps University Marburg
PharmaMar
University of British Columbia
Pfizer
Arbutus Biopharma Corporation
University of California, San Francisco
Esanex Inc.
Yale University
National Institutes of Health Clinical Center (CC)
Novartis
Hospices Civils de Lyon
Federation Francophone de Cancerologie Digestive
National Institutes of Health Clinical Center (CC)
University Hospital, Basel, Switzerland
Merck Sharp & Dohme LLC
Novartis
INSYS Therapeutics Inc
Delcath Systems Inc.
Memorial Sloan Kettering Cancer Center
Novartis
Novartis
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Exelixis
National Cancer Institute (NCI)
Assistance Publique - Hôpitaux de Paris
Adherex Technologies, Inc.